Inhibikase Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2024, on November 14, 2024. The company recorded a net loss of $5.8 million, or $0.65 per share, for the quarter.
This compares to a net loss of $4.6 million, or $0.75 per share, in the prior year's third quarter. Research and development expenses increased to $4.2 million for the quarter, up from $3.23 million in the same period of 2023.
Selling, general and administrative expenses remained relatively stable at $1.6 million for the quarter, compared to $1.62 million in the third quarter of 2023. As of September 30, 2024, cash, cash equivalents, and marketable securities stood at $3.2 million, not including the gross proceeds from the October 2024 financing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.